Avenue Therapeutics' AJ201: A Buy Rating for Innovative SBMA Treatment and Promising Clinical Progress
Buy Rating Affirmed for Avenue Therapeutics Amid Strong Prospects for IV Tramadol and Strategic Growth Potential
Analysts Conflicted on These Healthcare Names: Avenue Therapeutics (ATXI) and Inovio Pharmaceuticals (INO)
Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75
Avenue Therapeutics Analyst Ratings
Aegis Capital Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $32
Analysts Are Bullish on Top Healthcare Stocks: Avenue Therapeutics (ATXI), Eli Lilly & Co (LLY)
No Data